Abstract
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the United States, with 48,000 deaths per year and an overall 5-year relative survival rate of only 10%. Early diagnosis and treatment is therefore essential for optimal clinical outcomes, as survival is largely dependent on cancer stage, with a 5-year survival rate of 39% for localized resectable disease compared with only 3% for metastatic disease. Endoscopic ultrasound (EUS) combined with fine-needle aspiration/biopsy (FNA/FNB) is the most accurate modality available for the diagnosis of pancreatic cancer. The ability to procure core tissue at EUS has enabled the conduct of molecular profiling studies and thereby delivery of targeted drug therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
